- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2466
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
MiR-608 overexpression in idiopathic pulmonary fibrosis (IPF) ; volume:21 ; number:1 ; day:5 ; month:1 ; year:2021 ; pages:1-6 ; date:12.2021
BMC pulmonary medicine ; 21, Heft 1 (5.1.2021), 1-6, 12.2021
- Urheber
-
Epstein Shochet, Gali
Israeli-Shani, Lilach
Kains, Isabelle
Wand, Ori
Shitrit, David
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12890-020-01377-3
- URN
-
urn:nbn:de:101:1-2021030923325195891820
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Epstein Shochet, Gali
- Israeli-Shani, Lilach
- Kains, Isabelle
- Wand, Ori
- Shitrit, David
- SpringerLink (Online service)
Ähnliche Objekte (12)
Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)
Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America
Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)
Fibroblast paracrine TNF-α signaling elevates integrin A5 expression in idiopathic pulmonary fibrosis (IPF)
The overexpression of peroxiredoxin-4 affects the progression of idiopathic pulmonary fibrosis
Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry
Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials
Idiopathic pulmonary fibrosis
Idiopathic Pulmonary Fibrosis
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls
Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)
Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America
Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)
Fibroblast paracrine TNF-α signaling elevates integrin A5 expression in idiopathic pulmonary fibrosis (IPF)
The overexpression of peroxiredoxin-4 affects the progression of idiopathic pulmonary fibrosis
Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry
Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials
Idiopathic pulmonary fibrosis
Idiopathic Pulmonary Fibrosis
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls
Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)
Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America
Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)
Fibroblast paracrine TNF-α signaling elevates integrin A5 expression in idiopathic pulmonary fibrosis (IPF)
The overexpression of peroxiredoxin-4 affects the progression of idiopathic pulmonary fibrosis
Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry
Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials
Idiopathic pulmonary fibrosis
Idiopathic Pulmonary Fibrosis
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis